ZTS · Zoetis Inc.
$117.892026-05-17Sector: Healthcare; Industry: Drug Manufacturers - Specialty & Generic; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$106
-9.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($98 · $123) Analysts Range ($135 · $160) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $7.8B | — | 38.3% | 18.2% | $2.4B | −$551MM | $1.9B | 7.3% | — | 26.9% | $9.1B | $4.64 | — |
| 2022.Q4 | $8.1B | 3.9% | 38.5% | 20.5% | $2.5B | −$1.3B | $1.2B | 8.3% | — | 25.7% | $10.2B | $4.82 | — |
| 2023.Q4 | $8.5B | 5.7% | 38.2% | 20.3% | $2.6B | −$1.1B | $1.5B | 8.0% | — | 24.3% | $11.2B | $5.34 | — |
| 2024.Q4 | $9.3B | 8.3% | 39.0% | 20.3% | $2.9B | $211MM | $3.1B | 8.6% | — | 25.6% | $11.3B | $5.67 | — |
| 2025.Q4 | $9.5B | 2.3% | 40.4% | 20.4% | $3.0B | −$795MM | $2.2B | 8.5% | — | 25.9% | $12.2B | $6.09 | 13.5 |
| italics below = DCF projection · 10yr Rev CAGR: 4.4% |
| 2026.Q4 | $9.9B | +4.7% | 40.5% | 20.4% | $3.2B | −$582MM | $2.6B | 7.5% | $2.4B | 25.5% | $12.8B | $6.85 | 17.2 |
| 2027.Q4 | $10.4B | +4.9% | 40.5% | 20.4% | $3.4B | −$644MM | $2.7B | 7.6% | $2.3B | 25.5% | $13.5B | $7.19 | 16.4 |
| 2028.Q4 | $10.9B | +5.0% | 40.5% | 20.3% | $3.5B | −$710MM | $2.8B | 7.7% | $2.3B | 25.5% | $14.2B | $7.56 | 15.6 |
| 2029.Q4 | $11.4B | +4.3% | 40.5% | 20.3% | $3.7B | −$644MM | $3.0B | 7.8% | $2.3B | 25.4% | $14.8B | $7.88 | 15.0 |
| 2030.Q4 | $11.9B | +4.2% | 40.5% | 20.2% | $3.8B | −$665MM | $3.2B | 7.9% | $2.2B | 25.3% | $15.5B | $8.22 | 14.3 |
|
| Term. Yr+ | $15.1B | 4.1% | 31.9% | 20.0% | $3.9B | −$775MM | $3.1B | 8.6% | $31.8B | 20.4% | — | — | — |
Active scenario IV: $106 (-9.7% vs market)